Protocol for the Development of a Core Domain Set for Hidradenitis Suppurativa Trial Outcomes

Overview

Journal BMJ Open

Specialty General Medicine

Date 2017 Feb 22

PMID 28219961

Citations 16

Authors

Linnea Thorlacius

John R Ingram

Amit Garg

Bente Villumsen

Solveig Esmann

Joslyn S Kirby

Alice B Gottlieb

Joseph F Merola

Robert Dellavalle

Robin Christensen

Gregor B E Jemec

Affiliations

Soon will be listed here.

Abstract

Introduction: Randomised controlled trials (RCTs) should have well-defined primary and secondary outcomes to answer questions generated by the main hypotheses. However, for the chronic, inflammatory skin disease hidradenitis suppurativa (HS), the reported outcome measures are numerous and diverse. A recent systematic review found a total of 30 outcome measure instruments in 12 RCTs. This use of a broad range of outcome measures can increase difficulties in interpretation and comparison of results and may potentially obstruct appropriate evidence synthesis by causing reporting bias. One strategy for dealing with these problems is to develop a core outcome set (COS). A COS is a list of outcomes that are meant as mandatory and should be measured and reported in all clinical trials. The aim of this study is to develop a COS for the management of HS.

Method And Analysis: An international steering group of researchers, clinicians and a patient research partner will guide the COS development. 6 stakeholder groups are involved: patients, dermatologists, surgeons, nurses, industry representatives and drug regulatory authorities. A 1:1 ratio of patients:healthcare professionals is aimed for. The initial list of candidate items will be obtained by combining three data sets: (1) a systematic review of the literature, (2) US and Danish qualitative interview studies involving patients with HS and (3) an online healthcare professional (HCP) item generation survey. To reach consensus on the COS, 4 anonymous online Delphi rounds are then planned together with 2 face-to-face consensus meetings (1 in Europe and 1 in the USA) to ensure global representation.

Ethics And Dissemination: The study will be performed according to the Helsinki declaration. All results from the study, including inconclusive or negative results, will be published in peer-reviewed indexed journals. The study will involve different stakeholder groups to ensure that the developed COS will be suitable and well accepted.

Citing Articles

Pyoderma gangrenosum refined elements for core item selection and evaluation (PRECISE-PG): a study protocol for reaching consensus on core outcome domain items in clinical trials of pyoderma gangrenosum.

Tobey T, Ortega-Loayza A, Choe S, Haddadin O, Bardazzi F, Croitoru D Arch Dermatol Res. 2025; 317(1):449.

PMID: 39979653 DOI: 10.1007/s00403-025-03920-w.

Treatment of Hidradenitis Suppurativa Evaluation Study: the THESEUS prospective cohort study.

Ingram J, Bates J, Cannings-John R, Collier F, Gibbons A, Harris C Health Technol Assess. 2023; 27(30):1-107.

PMID: 38149635 PMC: 11017627. DOI: 10.3310/HWNM2189.

Overview and comparison of the clinical scores in hidradenitis suppurativa: A real-life clinical data.

Daoud M, Suppa M, Benhadou F, Daxhelet M, Njimi H, White J Front Med (Lausanne). 2023; 10:1145152.

PMID: 37138732 PMC: 10149852. DOI: 10.3389/fmed.2023.1145152.

Novel mixed-method, inclusive protocol involving global key stakeholders, including carers as experts, to co-develop relevant Caregiver-Reported Outcome Domains (CRODs) in skin disease.

Walsh C, Leavey G, Mc Laughlin M, Paller A, Irvine A, Browne F BMJ Open. 2023; 13(1):e068893.

PMID: 36657764 PMC: 9853252. DOI: 10.1136/bmjopen-2022-068893.

The "Understanding Pyoderma Gangrenosum, Review and Assessment of Disease Effects (UPGRADE)" Project: a protocol for the development of the core outcome domain set for trials in pyoderma gangrenosum.

Rick J, Gould L, Marzano A, Garg A, Chen D, Oakes D Arch Dermatol Res. 2022; 315(4):983-988.

PMID: 36305958 DOI: 10.1007/s00403-022-02424-1.

References

Kimball A, Kerdel F, Adams D, Mrowietz U, Gelfand J, Gniadecki R . Adalimumab for the treatment of moderate to severe Hidradenitis suppurativa: a parallel randomized trial. Ann Intern Med. 2012; 157(12):846-55. DOI: 10.7326/0003-4819-157-12-201212180-00004. View

Sartorius K, Killasli H, Heilborn J, Jemec G, Lapins J, Emtestam L . Interobserver variability of clinical scores in hidradenitis suppurativa is low. Br J Dermatol. 2010; 162(6):1261-8. DOI: 10.1111/j.1365-2133.2010.09715.x. View

Jemec G, Heidenheim M, Nielsen N . Hidradenitis suppurativa--characteristics and consequences. Clin Exp Dermatol. 1996; 21(6):419-23. DOI: 10.1111/j.1365-2230.1996.tb00145.x. View

Guyatt G, Oxman A, Kunz R, Atkins D, Brozek J, Vist G . GRADE guidelines: 2. Framing the question and deciding on important outcomes. J Clin Epidemiol. 2011; 64(4):395-400. DOI: 10.1016/j.jclinepi.2010.09.012. View

Tugwell P, Boers M, Brooks P, Simon L, Strand V, Idzerda L . OMERACT: an international initiative to improve outcome measurement in rheumatology. Trials. 2007; 8:38. PMC: 2169260. DOI: 10.1186/1745-6215-8-38. View

Matusiak L, Bieniek A, Szepietowski J . Hidradenitis suppurativa markedly decreases quality of life and professional activity. J Am Acad Dermatol. 2010; 62(4):706-8, 708.e1. DOI: 10.1016/j.jaad.2009.09.021. View

Williamson P, Altman D, Blazeby J, Clarke M, Devane D, Gargon E . Developing core outcome sets for clinical trials: issues to consider. Trials. 2012; 13:132. PMC: 3472231. DOI: 10.1186/1745-6215-13-132. View

Dufour D, Emtestam L, Jemec G . Hidradenitis suppurativa: a common and burdensome, yet under-recognised, inflammatory skin disease. Postgrad Med J. 2014; 90(1062):216-21. PMC: 3963556. DOI: 10.1136/postgradmedj-2013-131994. View

Cooney R, Warren B, Altman D, Abreu M, Travis S . Outcome measurement in clinical trials for Ulcerative Colitis: towards standardisation. Trials. 2007; 8:17. PMC: 1919394. DOI: 10.1186/1745-6215-8-17. View

10.

Harman N, Bruce I, Callery P, Tierney S, Sharif M, OBrien K . MOMENT--Management of Otitis Media with Effusion in Cleft Palate: protocol for a systematic review of the literature and identification of a core outcome set using a Delphi survey. Trials. 2013; 14:70. PMC: 3716725. DOI: 10.1186/1745-6215-14-70. View

11.

Esmann S, Jemec G . Psychosocial impact of hidradenitis suppurativa: a qualitative study. Acta Derm Venereol. 2011; 91(3):328-32. DOI: 10.2340/00015555-1082. View

12.

Revuz J, Canoui-Poitrine F, Wolkenstein P, Viallette C, Gabison G, Pouget F . Prevalence and factors associated with hidradenitis suppurativa: results from two case-control studies. J Am Acad Dermatol. 2008; 59(4):596-601. DOI: 10.1016/j.jaad.2008.06.020. View

13.

Ingram J, Hadjieconomou S, Piguet V . Development of core outcome sets in hidradenitis suppurativa: systematic review of outcome measure instruments to inform the process. Br J Dermatol. 2016; 175(2):263-72. DOI: 10.1111/bjd.14475. View

14.

Jemec G, Heidenheim M, Nielsen N . The prevalence of hidradenitis suppurativa and its potential precursor lesions. J Am Acad Dermatol. 1996; 35(2 Pt 1):191-4. DOI: 10.1016/s0190-9622(96)90321-7. View

15.

Sinha I, Smyth R, Williamson P . Using the Delphi technique to determine which outcomes to measure in clinical trials: recommendations for the future based on a systematic review of existing studies. PLoS Med. 2011; 8(1):e1000393. PMC: 3026691. DOI: 10.1371/journal.pmed.1000393. View

16.

Vinding G, Miller I, Zarchi K, Ibler K, Ellervik C, Jemec G . The prevalence of inverse recurrent suppuration: a population-based study of possible hidradenitis suppurativa. Br J Dermatol. 2013; 170(4):884-9. DOI: 10.1111/bjd.12787. View

17.

Wolkenstein P, Loundou A, Barrau K, Auquier P, Revuz J . Quality of life impairment in hidradenitis suppurativa: a study of 61 cases. J Am Acad Dermatol. 2006; 56(4):621-3. DOI: 10.1016/j.jaad.2006.08.061. View

18.

Jemec G . Clinical practice. Hidradenitis suppurativa. N Engl J Med. 2012; 366(2):158-64. DOI: 10.1056/NEJMcp1014163. View

19.

Kirkham J, Gargon E, Clarke M, Williamson P . Can a core outcome set improve the quality of systematic reviews?--a survey of the Co-ordinating Editors of Cochrane Review Groups. Trials. 2013; 14:21. PMC: 3575292. DOI: 10.1186/1745-6215-14-21. View

20.

Boers M, Kirwan J, Wells G, Beaton D, Gossec L, DAgostino M . Developing core outcome measurement sets for clinical trials: OMERACT filter 2.0. J Clin Epidemiol. 2014; 67(7):745-53. DOI: 10.1016/j.jclinepi.2013.11.013. View